 - Patient must have relapsed or refractory CLLSLL following at least one purine analog-containing regimen or after one non-purine analog containing regimen if there is a relative contraindication to purine-analog containing therapy and not have traditional options available or decline these. Patients with prolymphocytic leukemia PLL-CLL or PLL transformation of CLL are eligible. 